Current Report Filing (8-k)
January 20 2017 - 4:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): January 18, 2017
Dimension Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
|
001-37601
|
|
46-3942159
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
840 Memorial Drive, 4th Floor
Cambridge, MA
|
|
02139
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code (617) 401-0011
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On January 18, 2017, Dimension Therapeutics, Inc. (the
Company), upon the recommendation of its Nominating and Corporate Governance Committee, elected John Hohneker, MD, an executive vice president and head of research and development at FORMA Therapeutics, Inc., to the Board of Directors of
the Company (the Board), effective January 18, 2017. Dr. Hohneker will serve as a Class I director, to serve until the Companys annual meeting of stockholders next following December 31, 2018, or until his
successor is duly elected and qualified or his earlier resignation or removal.
Dr. Hohneker will be compensated for his service as a
non-employee director under the Companys Amended and Restated Non-Employee Director Compensation Policy (the Policy). In connection with his election and in accordance with the Policy, the Company granted Dr. Hohneker an
option to purchase 38,000 shares of the Companys common stock pursuant to the Companys 2015 Stock Option and Incentive Plan. As a non-employee director, Dr. Hohneker is also entitled to receive an annual service retainer of $35,000
and additional annual stock option awards, subject to his continued service on the Board.
The Company also expects to enter into an
indemnification agreement with Dr. Hohneker in connection with his appointment to the Board, which is expected to be in substantially the same form as that entered into with the other directors of the Company. There are no arrangements or
understandings between Dr. Hohneker and any other persons pursuant to which he was elected as a director, and Dr. Hohneker has no direct or indirect material interest in any transaction required to be disclosed pursuant to
Item 404(a) of Regulation S-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Date: January 20, 2017
|
|
|
|
DIMENSION THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Jean Franchi
|
|
|
|
|
|
|
Jean Franchi
|
|
|
|
|
|
|
Chief Financial Officer
|
DIMENSION THERAPEUTICS, INC. (NASDAQ:DMTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
DIMENSION THERAPEUTICS, INC. (NASDAQ:DMTX)
Historical Stock Chart
From Apr 2023 to Apr 2024